Pelvic inflammatory disease (PID), the infection and inflammation of a woman's upper genital tract, is a frequent cause of infertility, ectopic pregnancy, and chronic pelvic pain among women of childbearing age. The management of PID has been largely based on the protocols issued by national or international institution. These guidelines recommended a broad-spectrum antibiotherapy in which quinolones continue to hold a key place. Yet, several significant facts such as the increase of quinolone-resistant gonococci and the emergence of 'new' pathogens have recently led us to reconsider the paradigms of the management of PID. This article reviewed lately published literatures on new bacteriological finding and recent antibiotics trials to delinate optimal regimen in managing PID. 
현재 사용되고 있는 권고안
대표적인 권고안은 다음과 같다.
1) The Centers for Diseases Control and Prevention
(CDC) in the US (2006) ( Table 1)   1 2) The European guideline for the management of pelvic inflammatory disease (2007) 2 3) The Royal College of Obstetricians and Gynaecologists (RCOG) in the UK (2008) 3 4) The practice guideline "pelvic inflammatory disease" 
